Sana Biotechnology Inc vs Clear Secure Inc — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Clear Secure Inc trades at $46.91 (market cap $4.98B). The key difference: Clear Secure Inc is far larger — about 4.4× Sana Biotechnology Inc's market cap, and Clear Secure Inc pays a 1.19% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | YOU | |
|---|---|---|
Market Cap | $1.13B | $4.98B |
Sector | Health | Technology |
52-Week High | $5.92 | $62.36 |
52-Week Low | $2.68 | $29.61 |
Enterprise Value | $1.05B | $4.13B |
Dividend Yield | — | 1.19% |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
CLEAR Secure (YOU) trades at $46.16, down 9.86% in the past 24 hours, approaching key support at $45. The stock shows strong fundamentals with Q2 2026 earnings beating expectations at $0.49 per share versus $0.40 expected, driven by 66.66% gross margins and 90.29% ROE. Recent news highlights enterprise expansion including corporate membership launches and airport service investments.
Outlook remains positive with revenue growth accelerating to $1.0B in 2026 and analyst consensus leaning bullish (44% Buy ratings). Key risks include competitive pressure in identity verification and execution of new corporate initiatives. The current dip may present a buying opportunity for growth investors given strong profitability metrics.
Trailing returns across standard periods
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →